Meropenem Qilu (Meropenem)

Meropenem binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final step of peptidoglycan cross‑linking. This disruption weakens the cell wall, leading to osmotic rupture and bacterial cell death, providing a bactericidal effect against a wide range of Gram‑negative and Gram‑positive organisms.

The dosing regimen for Meropenem Qilu is determined by the prescribing clinician based on infection severity, site, and patient renal function. Dosage adjustments may be required for patients with impaired kidney function, and the medication is administered intravenously under professional supervision.

Safety data for meropenem in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the Meropenem Qilu product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meropenem shares the broad‑spectrum activity of the carbapenem class but offers a slightly higher stability against certain beta‑lactamases compared with imipenem. It is often preferred for infections caused by resistant Gram‑negative pathogens, while dosing flexibility and renal adjustment are similar across carbapenems.

Meropenem Qilu should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light to maintain potency until reconstitution for intravenous administration.

The product is supplied as a sterile powder for reconstitution. After proper dilution with compatible IV fluids, it is administered intravenously over a prescribed infusion period, typically 15–30 minutes, under clinical supervision.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, and severe hypersensitivity reactions such as anaphylaxis. Prompt recognition and discontinuation are essential if these events occur.

Patients with a documented hypersensitivity to meropenem, other carbapenems, or any beta‑lactam antibiotics should avoid this product. Caution is also advised for individuals with severe renal dysfunction, uncontrolled epilepsy, or those receiving valproic acid without close monitoring.